H6D0 Stock Chart & Stats
€4.48
-€0.01(-0.22%)
At close: 4:00 PM EDT
€4.48
-€0.01(-0.22%)
Day’s Range― - ―
52-Week Range€3.72 - €4.78
Previous CloseN/A
Volume16.56K
Average Volume (3M)9.90K
Market Cap
€37.39B
Enterprise Value€38.50K
Total Cash (Recent Filing)€1.32B
Total Debt (Recent Filing)€8.58B
Price to Earnings (P/E)19.6
Beta0.15
Next Earnings
Mar 04, 2027EPS Estimate
0.12Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.18
Shares Outstanding8,808,899,000
10 Day Avg. Volume11,677
30 Day Avg. Volume9,901
Financial Highlights & Ratios
PEG Ratio1.05
Price to Book (P/B)2.05
Price to Sales (P/S)3.05
P/FCF Ratio16.67
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€4.52Price Target Upside0.98% Upside
Rating ConsensusHold
Number of Analyst Covering8
EPS Forecast (FY)<0.01
Revenue Forecast (FY)€133.25M
Bulls Say, Bears Say
Bulls Say
Consistent Free Cash Flow GenerationDurable, high-quality cash generation (~1.7–2.0B FCF) provides recurring internal funding for A&P, R&D, debt reduction and capex. This persistent cash conversion supports strategic reinvestment and financial flexibility, cushioning the company through cycles and enabling execution of medium-term initiatives.
Material Margin Gains And ProductivityA one-off 220bps gross margin uplift, driven by SKU rationalisation and supply‑chain changes, reflects durable structural efficiency gains. OEE up 7 points and planned 50–80bps ongoing productivity imply sustained margin headroom that can fund reinvestment and improve operating leverage over multiple years.
Emerging Markets And E‑commerce MomentumStrong execution in India and China reflects structural growth tailwinds: rural expansion, low‑price packs and rapid e‑commerce adoption. Higher digital share and Douyin-led growth point to scalable routes to market and sustained top‑line upside in faster-growing geographies over the medium term.
Bears Say
Weak Volume Growth Versus PeersPersistent low volume contribution (~1% average) suggests structural demand or execution gaps that limit organic top‑line expansion. Reliance on pricing or mix to hit growth targets risks sustainability; the company must materially lift unit growth to reliably deliver 4–6% medium‑term ambitions.
Recurring Cold & Flu And Category-specific WeaknessRepeated weak cold & flu seasons reduce baseline category demand and have depressed U.S. and global performance. As a core OTC category, structural softness and channel destocking can persist across seasons, constraining sustainable growth and complicating inventory and promotional planning.
Elevated Leverage And Shrinking Asset BaseAlthough recent debt reduction is positive, leverage is still elevated versus pre‑spin years and assets have declined, reducing financial flexibility. Higher structural leverage limits scope for aggressive M&A or rate‑sensitive investments and increases vulnerability to macro shocks over the medium term.
Haleon PLC News
H6D0 FAQ
What was Haleon PLC’s price range in the past 12 months?
Haleon PLC lowest stock price was €3.71 and its highest was €4.78 in the past 12 months.
What is Haleon PLC’s market cap?
Haleon PLC’s market cap is €37.39B.
When is Haleon PLC’s upcoming earnings report date?
Haleon PLC’s upcoming earnings report date is Mar 04, 2027 which is in 213 days.
How were Haleon PLC’s earnings last quarter?
Haleon PLC released its earnings results on Jul 30, 2026. The company reported €0.05 earnings per share for the quarter, missing the consensus estimate of €0.057 by -€0.007.
Is Haleon PLC overvalued?
According to Wall Street analysts Haleon PLC’s price is currently Undervalued.
Does Haleon PLC pay dividends?
Haleon PLC does not currently pay dividends.
What is Haleon PLC’s EPS estimate?
Haleon PLC’s EPS estimate is 0.12.
How many shares outstanding does Haleon PLC have?
Haleon PLC has 8,808,899,000 shares outstanding.
What happened to Haleon PLC’s price movement after its last earnings report?
Haleon PLC reported an EPS of €0.05 in its last earnings report, missing expectations of €0.057. Following the earnings report the stock price went down -2.93%.
Which hedge fund is a major shareholder of Haleon PLC?
Currently, no hedge funds are holding shares in DE:H6D0
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Haleon PLC Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
€4.52 (0.98% Upside)
€4.52 (0.98% Upside)
Blogger Sentiment
Bullish
DE:H6D0 Sentiment 100%
Sector Average ―
Sector Average ―
Insider Transactions
Sold Shares
Worth £469.7K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-6.29%
12-Months-Change
Fundamentals
Return on Equity
1.91%
Trailing 12-Months
Asset Growth
2.37%
Trailing 12-Months
Company Description
Haleon PLC
Haleon plc operates as a global entity focused on developing, manufacturing, and marketing an array of consumer health products. Its operations extend across multiple continents, specifically North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company offers a comprehensive selection of items, encompassing therapeutic oral care, pain relief solutions, respiratory health aids, digestive wellness products, as well as vitamins, minerals, and other dietary supplements. Prominent brands within its extensive portfolio include Panadol, Voltaren, Advil, Otrivin, Theraflu, Sensodyne, Polident, parodontax, and Centrum. The firm, incorporated in 2021, was initially named DRVW 2022 plc before rebranding to Haleon plc in February 2022. Its corporate headquarters are located in Brentford, United Kingdom.
H6D0 Stock 12 Month Forecast
Average Price Target
€4.52
▲(0.98% Upside)
Technical Analysis
Allergy Therapeutics
―
Provexis
―
Shield Therapeutics
―
Venture Life
―
Beximco Pharmaceuticals Limited Sponsored GDR RegS
―